Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
No Thumbnail Available
Authors
Nauck, M. A.
Stewart, M. W.
Perkins, C.
Jones-Leone, A.
Yang, F.
Perry, C.
Reinhardt, R. R.
Rendell, M.
Issue Date
2016
Type
Journal Article
Language
eng_US
Keywords
Alternative Title
Abstract
Description
Citation
Nauck, M. A.; Stewart, M. W.; Perkins, C.; Jones-Leone, A.; Yang, F.; Perry, C.; Reinhardt, R. R.; Rendell, M. (2016). Efficacy and Safety of Once-Weekly GLP-1 Receptor Agonist Albiglutide (HARMONY 2): 52 Week Primary Endpoint Results from a Randomised, Placebo-Controlled Trial in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise. Diabetologia, 2016 February, 59(2):266-274. doi: http://doi.org/10.1007/s00125-015-3795-1
Publisher
License
Journal
Volume
Issue
PubMed ID
DOI
ISSN
1432-0428
0012-186X
0012-186X